BioPorto Diagnostics A/S Revenue
Biotechnology Research • 
Copenhagen, Capital Region of Denmark, Denmark • 21-50 Employees
BioPorto Diagnostics A/S revenue & valuation
| Annual revenue | $5,147,492 |
| Revenue per employee | $123,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $16,500,000 |
| Total funding | $16,910,000 |
Key Contacts at BioPorto Diagnostics A/S
Erik Melgaard Pedersen
Regional Sales Director
Helle Helena Kirkemann
Head Of Group Hr & Esg, Director
Thomas Arvedsen
Director Of Production
Monika Bak Phd Rac
Director Regulatory Affairs
Jacqueline Alarie
Regional Sales Director
Company overview
| Headquarters | Copenhagen, Capital Region of Denmark, Denmark |
| Phone number | +4545290000 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Assay Development, Clinical Research, Diagnostics, Antibodies, Research & Development, Acute Kidney Injury (Aki) Biomarker, Appetite Regulating Hormones, Complement And Innate Immunity, In-Vitro Diagnostics (Ivd), Pre-Clinical, Fda Qualified Biomarker (Bqp), Lateral Flow Assay Development (Grad), Ngal Elisa Kits (Human And Animal, Ngal Biomarker, Drug Induced Kidney Injury (Diki), Generic Rapid Assay Device (Grad), Non-Clinical Research, Scientific And Pre-Clinical Drug Research |
| Employees | 21-50 |
| Socials |
BioPorto Diagnostics A/S Email Formats
BioPorto Diagnostics A/S uses 1 email format. The most common is {2char} (e.g., {2char}@bioporto.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{2char} | {2char}@bioporto.com | 100% |
About BioPorto Diagnostics A/S
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products, ProNephro AKI™ and The NGAL Test™, are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, clinicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark, and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. To learn more about our products and their availability in your country, please visit https://bioporto.com/products/. Posts are not intended for a U.S. audience. If you are from the United States, you are encouraged to visit https://www.linkedin.com/company/bioporto-diagnostics-inc-us/ Social Media Community Guidelines: https://bioporto.com/social-media/
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
BioPorto Diagnostics A/S has 24 employees across 10 departments.
Departments
Number of employees
Funding Data
Explore BioPorto Diagnostics A/S's funding history, including investment rounds, total capital raised, and key backers.
BioPorto Diagnostics A/S Tech Stack
Discover the technologies and tools that power BioPorto Diagnostics A/S's digital infrastructure, from frameworks to analytics platforms.
Video players
Security
Form builders
JavaScript libraries
JavaScript frameworks
JavaScript libraries
UI frameworks
JavaScript libraries
Page builders
JavaScript libraries
CDN
China
United Kingdom
Frequently asked questions
4.8
40,000 users
